[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

November 19, 2020
Original Investigation

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5945

This single-arm, phase 2 nonrandomized clinical trial assesses the efficacy and safety of combined pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide in women with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation

Abstract Full Text
open access
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5957

This cohort study investigates the long-term reproductive outcomes in women who did or did not undergo fertility preservation at the time of breast cancer diagnosis.

Research Letter

Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models

Abstract Full Text
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5585

This cohort study assesses the concordance of 3 models to stratify risk for progression to multiple myeloma in an independent cohort of patients with smoldering multiple myeloma.

Review

Nonpharmacological Interventions for Managing Breathlessness in Patients With Advanced Cancer: A Systematic Review

Abstract Full Text
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5184

This systematic review reports the outcomes and evidence in randomized clinical trials of nonpharmacological treatment options for alleviating breathlessness and their implications for clinical guidelines and practice in advanced cancer.

Viewpoint

Financial Toxicity From Generic Specialty Drug Use

Abstract Full Text
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5181

This Viewpoint argues that specialty generics can cost more for patients than brand-name drugs, and proposes strategies to protect patients by addressing the market dysfunction caused by rebates.

Comment & Response

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy

Abstract Full Text
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5582

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy—Reply

Abstract Full Text
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.5591
Correction

Error in Author Byline Order

Abstract Full Text
free access
JAMA Oncol. Published online November 19, 2020. doi:10.1001/jamaoncol.2020.6492
November 12, 2020
Original Investigation

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

Abstract Full Text
has audio
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5774

This nonrandomized clinical trial evaluates molecular recurrence and patient-reported outcomes after tyrosine kinase inhibitor discontinuation in US patients with chronic myeloid leukemia.

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial

Abstract Full Text
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5865

This nonrandomized controlled trial reports the oncological outcomes of the deintensification (from 50 Gy to 36 Gy) of a preoperative radiotherapy regimen for adults with myxoid liposarcoma.

Brief Report

Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer:

Abstract Full Text
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5671

This case series examines clinical characteristics, experiences, and outcomes of transgender patients with cancer.

Research Letter

Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials

Abstract Full Text
open access has active quiz
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5748

This survey study examines the attitudes of a large group of cancer survivors toward trial participation during the coronavirus disease 2019 outbreak.

JAMA Oncology Clinical Challenge

Scalp Eruption in a Patient With Metastatic Colon Cancer

Abstract Full Text
has active quiz
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5176

A 73-year-old man with metastatic colorectal cancer presents with crusted lesions and purulent drainage on the scalp, with associated pruritus and pain. What is your diagnosis?

Invited Commentary

Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse

Abstract Full Text
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5772
Cancer Care Chronicles

Hope Shattered, Hope Restored

Abstract Full Text
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5191

This essay describes how an act of kindness can restore one’s hope.

Comment & Response

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases

Abstract Full Text
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5466

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases—Reply

Abstract Full Text
JAMA Oncol. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5473
November 5, 2020
Original Investigation

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5660

This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count–driven choice for first-line treatment among women with hormone receptor–positive, ERBB2-negative metastatic breast cancer.

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5572

This randomized clinical trial evaluates clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.

Brief Report

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

Abstract Full Text
open access
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5161

This case series study examines the prevalence of clonal hematopoiesis and its potential interference in prostate cancer cell-free DNA testing.

Research Letter

Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates

Abstract Full Text
open access has active quiz
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5745

This cohort study examines the implementation of a microbiologic screening pilot program in Al Zahra Hospital in the United Arab Emirates for identifying presymptomatic COVID-19 in patients with cancer.

Viewpoint

Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap?

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.4811

This Viewpoint discusses approvals by the US Food and Drug Administration for first- and second-line chemotherapy drugs—plus the combined use of some agents—used to treat hepatocellular carcinoma.

Editorial

Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer—Is Not Worse Good Enough?

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5460
Invited Commentary

A CHIP in the Armor of Cell-Free DNA–Based Predictive Biomarkers for Prostate Cancer

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5140
Comment & Response

Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5158

Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma—Reply

Abstract Full Text
JAMA Oncol. Published online November 5, 2020. doi:10.1001/jamaoncol.2020.5167
×